Latest News

Home monitoring enhances pediatric asthma management, boosting patient engagement and awareness while providing valuable medical feedback for better control.

Young adults with high LDL-C levels face significant gaps in statin initiation and follow-up testing, highlighting urgent needs for improved cardiovascular care.

New findings reveal lorundrostat significantly lowers blood pressure and albuminuria in patients with chronic kidney disease, enhancing standard treatment efficacy.

Amir Masood, PharmD, is director of pharmacy operations at Safeway – Mid-Atlantic Division.

New research shows that an increased consumption of ultraprocessed foods significantly raises prediabetes risk in young adults, highlighting urgent dietary intervention needs.

The FDA approves Poherdy, a new biosimilar to Perjeta, enhancing treatment options for HER2+ breast cancer patients with affordability and efficacy.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Ziftomenib gains FDA approval as a targeted treatment for relapsed acute myeloid leukemia with NPM1 mutations, offering new hope for patients.

CAR T-cell therapy revolutionizes cancer treatment but poses significant financial and logistical burdens, impacting patient access and outcomes.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

A nasal vaccine against whooping cough shows promise in blocking infection and enhancing respiratory immunity, offering a needle-free solution.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

Only Humans Can Ensure AI Is Ethical and Unbiased

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

Semaglutide shows significant weight loss and reduces obesity-related health risks, offering a promising solution for effective weight management.

The new year can present challenges to health-system pharmacy.

Metformin may hinder exercise benefits, impacting blood vessel function and insulin control, raising concerns for diabetes management during physical activity.

At 3 and 9 months, inclisiran reduced low-density lipoprotein cholesterol in patients intolerant to statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors at rates comparable to those in placebo-controlled trials.

The Latest Kaiser Family Foundation Employer Health Benefits Survey Has Unsurprising but Consequential Findings